All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Korea's largest pharmaceutical company, Yuhan Corp., and German giant Boehringer Ingelheim GmbH (BI) have signed a collaboration and license agreement to develop a first-in-class dual agonist to treat nonalcoholic steatohepatitis (NASH) and related liver diseases, following a similar path trod by other companies.